Literature DB >> 17297411

Inhibition of heart allograft rejection with mitomycin C-treated donor dendritic cells.

Lucian P Jiga1, Sandra Ehser, Christian Kleist, Gerhard Opelz, Peter Terness.   

Abstract

We showed previously that dendritic cells (DCs) treated with mitomycin C (MMC) tolerize allogeneic T cells in vitro and this might be mediated by downregulation of CD80, CD86, and ICAM-1. Here we analyze the suppression of the T-cell response induced by MMC-DCs in vivo. Rats injected with allogeneic DCs developed a strong lymph node reaction, whereas MMC-DCs induced no reaction. The same effect was obtained when CD80, CD86, and ICAM-1 expressed by DCs were blocked with antibodies. One injection of donor MMC-DCs strongly prolonged heart allograft survival in a donor-specific manner. Suppression of rejection was also achieved when donor DCs were pretreated with a combination of anti-CD80, anti-CD86, and anti-ICAM-1 antibodies, showing that downregulation of these molecules confers the DCs inhibitory properties. We conclude that allogeneic MMC-DCs specifically inhibit the T-cell response in vivo and that downregulation of CD80, CD86, and ICAM-1 is a potential mechanism of this effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297411     DOI: 10.1097/01.tp.0000248854.30016.11

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  A propos time and autoimmunity.

Authors:  Pablo I Martín; Ana I Malizia; E Rewald
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 2.  Cell therapy for immunosuppression after kidney transplantation.

Authors:  Christian Morath; Anita Schmitt; Martin Zeier; Michael Schmitt; Flavius Sandra-Petrescu; Gerhard Opelz; Peter Terness; Matthias Schaier; Christian Kleist
Journal:  Langenbecks Arch Surg       Date:  2015-06-17       Impact factor: 3.445

Review 3.  Cell therapeutic approaches to immunosuppression after clinical kidney transplantation.

Authors:  Christian Morath; Anita Schmitt; Florian Kälble; Martin Zeier; Michael Schmitt; Flavius Sandra-Petrescu; Gerhard Opelz; Peter Terness; Matthias Schaier; Christian Kleist
Journal:  Pediatr Nephrol       Date:  2017-02-23       Impact factor: 3.714

4.  Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches.

Authors:  Irina Zakharova; Shoraan Saaya; Alexander Shevchenko; Alena Stupnikova; Maria Zhiven'; Pavel Laktionov; Alena Stepanova; Alexander Romashchenko; Lyudmila Yanshole; Alexander Chernonosov; Alexander Volkov; Elena Kizilova; Evgenii Zavjalov; Alexander Chernyavsky; Alexander Romanov; Andrey Karpenko; Suren Zakian
Journal:  Front Bioeng Biotechnol       Date:  2022-03-11

5.  Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases.

Authors:  Peter Terness; Thilo Oelert; Sandra Ehser; Jing Jing Chuang; Imad Lahdou; Christian Kleist; Florian Velten; Günter J Hämmerling; Bernd Arnold; Gerhard Opelz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-18       Impact factor: 11.205

6.  Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.

Authors:  Christian Kleist; Elisabeth Mohr; Sadanand Gaikwad; Laura Dittmar; Stefanie Kuerten; Michael Platten; Walter Mier; Michael Schmitt; Gerhard Opelz; Peter Terness
Journal:  J Transl Med       Date:  2016-05-01       Impact factor: 5.531

Review 7.  Effects of Adoptive Transfer of Tolerogenic Dendritic Cells on Allograft Survival in Organ Transplantation Models: An Overview of Systematic Reviews.

Authors:  Yanni Zhou; Juan Shan; Yingjia Guo; Shengfu Li; Dan Long; Youping Li; Li Feng
Journal:  J Immunol Res       Date:  2016-07-28       Impact factor: 4.818

Review 8.  Cellular Therapies in Solid Organ Allotransplantation: Promise and Pitfalls.

Authors:  Brian I Shaw; Jeffrey R Ord; Chloe Nobuhara; Xunrong Luo
Journal:  Front Immunol       Date:  2021-08-30       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.